Author： Kappelhoff Bregt S. Huitema Alwin D.R. Beijnen Jos H.
Publisher： Adis International
ISSN： 1174-5886
Source： Drugs in R&D, Vol.6, Iss.2, 2005-01, pp. : 61-69
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Do Non-Nucleoside Reverse Transcriptase Inhibitors Contribute to Lipodystrophy?
By Nolan David
Drug Safety, Vol. 28, Iss. 12, 2005-01 ,pp. :
Access to resources
Recommend
Non-nucleoside inhibitors of HIV-1 reverse transcriptase
Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 8, 1998-08 ,pp. :
Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors
By Smith P.F.
Clinical Pharmacokinetics, Vol. 40, Iss. 12, 2001-01 ,pp. :
HIV-1 non-nucleoside reverse transcriptase inhibitors
Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 8, 2000-08 ,pp. :